Skip to content
2000
Volume 26, Issue 11
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Background

Atopic Dermatitis (AD) is an inflammatory skin condition with a severe itch. The topical therapy using corticosteroids is not sufficient for the effective therapy of moderate to severe cases of AD. The investigation and development of immunological target-specific human monoclonal antibodies have changed the paradigm for the therapy of moderate to severe cases of AD.

Objective

The establishment of target-specific, tolerable, and efficacious human monoclonal antibodies might lead to the better management of moderate to severe cases of AD.

Methodology

The scientific literature available in databases, such as Pubmed and Clinicaltrial.gov, was searched and discussed for available clinical therapeutic information.

Discussion

The present review has discussed the potential immunological targets of specific monoclonal antibodies developed and approved or which are under investigation in clinical trials.

Conclusion

The development of targeted monoclonal antibodies can improve the understanding of the role of different immunological pathways and biomarkers in AD and become the future of AD treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010311098240530104530
2024-06-25
2025-09-04

  • From This Site

    /content/journals/cpb/10.2174/0113892010311098240530104530
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KumarP. SharmaD.K. AshawatM.S. Traditional herbal medicines, newer herbs and other novel approaches integrated in herbal medicine for atopic dermatitis-a narrative review.Curr. Drug Ther.202015319420810.2174/1574885514666191018165209
     [Google Scholar]
  2. Renert-YuvalY. Guttman-YasskyE. Monoclonal antibodies for the treatment of atopic dermatitis.Curr. Opin. Allergy Clin. Immunol.201818435636410.1097/ACI.0000000000000455 29870461
     [Google Scholar]
  3. KumarP. SharmaD.K. AshawatM.S. Pathophysioloy and management of atopic dermatitis: A Laconic review.Curr. Drug Ther.202015432133610.2174/1574885514666190828152316
     [Google Scholar]
  4. VakhariaP.P. SilverbergJ.I. Monoclonal antibodies for atopic dermatitis: Progress and potential.BioDrugs201731540942210.1007/s40259‑017‑0241‑6 28853008
     [Google Scholar]
  5. KumarP. AshawatM.S. PanditV. Singh VermaC.P. AnkalgiA.D. KumarM. Recent trends in nanocarriers for the management of atopic dermatitis.Pharm. Nanotechnol.202311539740910.2174/2211738511666230330115229 36998138
     [Google Scholar]
  6. WallingH. SwickB.L. Update on the management of chronic eczema: New approaches and emerging treatment options.Clin. Cosmet. Investig. Dermatol.201039911710.2147/CCID.S6496 21437065
     [Google Scholar]
  7. EichenfieldL.F. TomW.L. BergerT.G. KrolA. PallerA.S. SchwarzenbergerK. BergmanJ.N. ChamlinS.L. CohenD.E. CooperK.D. CordoroK.M. DavisD.M. FeldmanS.R. HanifinJ.M. MargolisD.J. SilvermanR.A. SimpsonE.L. WilliamsH.C. ElmetsC.A. BlockJ. HarrodC.G. BegolkaW.S. SidburyR. Guidelines of care for the management of atopic dermatitis.J. Am. Acad. Dermatol.201471111613210.1016/j.jaad.2014.03.023 24813302
     [Google Scholar]
  8. Montes-TorresA. Llamas-VelascoM. Pérez-PlazaA. Solano-LópezG. Sánchez-PérezJ. Biological treatments in atopic dermatitis.J. Clin. Med.20154459361310.3390/jcm4040593 26239349
     [Google Scholar]
  9. HarskampC. ArmstrongA. Immunology of atopic dermatitis: Novel insights into mechanisms and immunomodulatory therapies.Semin. Cutan. Med. Surg.201332313213910.12788/j.sder.0018 24175400
     [Google Scholar]
  10. IblerK.S. JemecG.B.E. Novel investigational therapies for atopic dermatitis.Expert Opin. Investig. Drugs2015241616810.1517/13543784.2015.957756 25201033
     [Google Scholar]
  11. SimpsonE.L. BieberT. Guttman-YasskyE. BeckL.A. BlauveltA. CorkM.J. SilverbergJ.I. DeleuranM. KataokaY. LacourJ.P. KingoK. WormM. PoulinY. WollenbergA. SooY. GrahamN.M.H. PirozziG. AkinladeB. StaudingerH. MasteyV. EckertL. GadkariA. StahlN. YancopoulosG.D. ArdeleanuM. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.N. Engl. J. Med.2016375242335234810.1056/NEJMoa1610020 27690741
     [Google Scholar]
  12. ThaçiD. SimpsonE.L. BeckL.A. BieberT. BlauveltA. PappK. SoongW. WormM. SzepietowskiJ.C. SofenH. KawashimaM. WuR. WeinsteinS.P. GrahamN.M.H. PirozziG. TeperA. SutherlandE.R. MasteyV. StahlN. YancopoulosG.D. ArdeleanuM. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial.Lancet201638710013405210.1016/S0140‑6736(15)00388‑8 26454361
     [Google Scholar]
  13. HamiltonJ.D. UngarB. Guttman-YasskyE. Drug evaluation review: Dupilumab in atopic dermatitis.Immunotherapy20157101043105810.2217/imt.15.69 26598956
     [Google Scholar]
  14. KoskeridisF. EvangelouE. NtzaniE.E. KostikasK. TsabouriS. Treatment with dupilumab in patients with atopic dermatitis: Systematic review and meta-analysis.J. Cutan. Med. Surg.202226661362110.1177/12034754221130969 36214355
     [Google Scholar]
  15. GooderhamM.J. HongH.C. EshtiaghiP. PappK.A. Dupilumab: A review of its use in the treatment of atopic dermatitis.J. Am. Acad. Dermatol.2018783Suppl. 1S28S3610.1016/j.jaad.2017.12.022 29471919
     [Google Scholar]
  16. ChuA.W.L. WongM.M. RaynerD.G. GuyattG.H. Díaz MartinezJ.P. CeccacciR. ZhaoI.X. McMullenE. SrivastavaA. WangJ. WenA. WangF.C. Brignardello-PetersenR. IzcovichA. OykhmanP. WheelerK.E. WangJ. SpergelJ.M. SinghJ.A. SilverbergJ.I. OngP.Y. O’BrienM. MartinS.A. LioP.A. LindM.L. LeBovidgeJ. KimE. HuynhJ. GreenhawtM. GardnerD.D. FrazierW.T. EllisonK. ChenL. CapozzaK. De BenedettoA. BoguniewiczM. Smith BegolkaW. AsiniwasisR.N. SchneiderL.C. ChuD.K. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.J. Allergy Clin. Immunol.202315261470149210.1016/j.jaci.2023.08.029 37678577
     [Google Scholar]
  17. XuY. GuoL. LiZ. WuS. JiangX. Efficacy and safety profile of dupilumab for the treatment of atopic dermatitis in children and adolescents: A systematic review and meta‐analysis.Pediatr. Dermatol.202340584185010.1111/pde.15398 37529963
     [Google Scholar]
  18. WollenbergA. HowellM.D. Guttman-YasskyE. SilverbergJ.I. BirrellC. KellC. RanadeK. DawsonM. Van der MerweR. A Phase 2b dose-ranging efficacy and safety study of Tralokinumab in adult patients with moderate to Severe Atopic Dermatitis.SKIN J. Cutaneous Med.20182S1S2910.25251/skin.2.supp.28
     [Google Scholar]
  19. PanettieriR.A.Jr WangM. BraddockM. BowenK. ColiceG. Tralokinumab for the treatment of severe, uncontrolled asthma: The ATMOSPHERE clinical development program.Immunotherapy201810647349010.2217/imt‑2017‑0191 29536781
     [Google Scholar]
  20. WollenbergA. HowellM.D. Guttman-YasskyE. SilverbergJ.I. KellC. RanadeK. MoateR. van der MerweR. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb.J. Allergy Clin. Immunol.2019143113514110.1016/j.jaci.2018.05.029 29906525
     [Google Scholar]
  21. SilverbergJ.I. TothD. BieberT. AlexisA.F. ElewskiB.E. PinkA.E. HijnenD. JensenT.N. BangB. OlsenC.K. KurbasicA. WeidingerS. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: Results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial.Br. J. Dermatol.2021184345046310.1111/bjd.19573 33000503
     [Google Scholar]
  22. WollenbergA. WeidingerS. WormM. BieberT. Tralokinumab in atopic dermatitis.J. Dtsch. Dermatol. Ges.2021191014351442 34390128
     [Google Scholar]
  23. WollenbergA. BlauveltA. Guttman-YasskyE. WormM. LyndeC. LacourJ.P. SpelmanL. KatohN. SaekiH. PoulinY. LesiakA. KircikL. ChoS.H. HerranzP. CorkM.J. PerisK. SteffensenL.A. BangB. KuznetsovaA. JensenT.N. ØsterdalM.L. SimpsonE.L. Tralokinumab for moderate‐to‐severe atopic dermatitis: Results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br. J. Dermatol.2021184343744910.1111/bjd.19574 33000465
     [Google Scholar]
  24. MüllerS. MaintzL. BieberT. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.Allergy202420241600910.1111/all.16009 38186219
     [Google Scholar]
  25. SimpsonE.L. FlohrC. EichenfieldL.F. BieberT. SofenH. TaïebA. OwenR. PutnamW. CastroM. DeBuskK. LinC.Y. VoulgariA. YenK. OmachiT.A. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).J. Am. Acad. Dermatol.2018785863871.e1110.1016/j.jaad.2018.01.017 29353026
     [Google Scholar]
  26. YosipovitchG. LioP.A. RosmarinD. Serra-BaldrichE. LegatF.J. CasillasM. PierceE. LiuZ. SunL. ElmaraghyH. StänderS. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: Two randomized, placebo-controlled, phase III trials.Br. J. Dermatol.2024190228929110.1093/bjd/ljad435 37939793
     [Google Scholar]
  27. Stein GoldL. ThaçiD. ThyssenJ.P. GooderhamM. LaquerV. MooreA. NatalieC.R. ZhaoF. MeskimenE. ElmaraghyH. MontmayeurS. GalloG. JimenezG. de Bruin-WellerM. Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: An integrated analysis of eight clinical trials.Am. J. Clin. Dermatol.202324459560710.1007/s40257‑023‑00792‑6 37195407
     [Google Scholar]
  28. BernardoD. BieberT. TorresT. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.Am. J. Clin. Dermatol.202324575376410.1007/s40257‑023‑00793‑5 37266844
     [Google Scholar]
  29. SimpsonE.L. GooderhamM. WollenbergA. Efficacy and safety of Lebrikizumab in combination with Topical Corticosteroids in adolescents and adults with Moderate-to-Severe Atopic Dermatitis.JAMA Dermatol.20231592182191
     [Google Scholar]
  30. SimpsonE.L. GooderhamM. WollenbergA. WeidingerS. ArmstrongA. SoungJ. FerrucciS. LimaR.G. WitteM.M. XuW. ElMaraghyH. NatalieC.R. PierceE. BlauveltA. Dermatitis: A randomized clinical trial (ADhere).JAMA Dermatol.2023159218219110.1001/jamadermatol.2022.5534 36630140
     [Google Scholar]
  31. SilverbergJ.I. Guttman-YasskyE. ThaçiD. IrvineA.D. Stein GoldL. BlauveltA. SimpsonE.L. ChuC.Y. LiuZ. Gontijo LimaR. PillaiS.G. SeneschalJ. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis.N. Engl. J. Med.2023388121080109110.1056/NEJMoa2206714 36920778
     [Google Scholar]
  32. PallerA.S. FlohrC. EichenfieldL.F. IrvineA.D. WeismanJ. SoungJ. Pinto CorreiaA. NatalieC.R. Rodriguez CaprilesC. PierceE. ReifeisS. Gontijo LimaR. Armengol TubauC. LaquerV. WeidingerS. Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study.Dermatol. Ther. (Heidelb.)20231371517153410.1007/s13555‑023‑00942‑y 37318750
     [Google Scholar]
  33. BlauveltA. ThyssenJ.P. Guttman-YasskyE. BieberT. Serra-BaldrichE. SimpsonE. RosmarinD. ElmaraghyH. MeskimenE. NatalieC.R. LiuZ. XuC. PierceE. Morgan-CoxM. Garcia GilE. SilverbergJ.I. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Br. J. Dermatol.2023188674074810.1093/bjd/ljad022 36994947
     [Google Scholar]
  34. Guttman-YasskyE. BlauveltA. EichenfieldL.F. PallerA.S. ArmstrongA.W. DrewJ. GopalanR. SimpsonE.L. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial.JAMA Dermatol.2020156441142010.1001/jamadermatol.2020.0079 32101256
     [Google Scholar]
  35. CevikbasF. WangX. AkiyamaT. KempkesC. SavinkoT. AntalA. KukovaG. BuhlT. IkomaA. BuddenkotteJ. SoumelisV. FeldM. AleniusH. DillonS.R. CarstensE. HomeyB. BasbaumA. SteinhoffM. A sensory neuron–expressed IL-31 receptor mediates T helper cell–dependent itch: Involvement of TRPV1 and TRPA1.J. Allergy Clin. Immunol.20141332448460.e710.1016/j.jaci.2013.10.048 24373353
     [Google Scholar]
  36. KatoA. FujiiE. WatanabeT. TakashimaY. MatsushitaH. FuruhashiT. MoritaA. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis.J. Dermatol. Sci.201474322923510.1016/j.jdermsci.2014.02.009 24667097
     [Google Scholar]
  37. DillonS.R. SprecherC. HammondA. BilsboroughJ. Rosenfeld-FranklinM. PresnellS.R. HaugenH.S. MaurerM. HarderB. JohnstonJ. BortS. MudriS. KuijperJ.L. BukowskiT. SheaP. DongD.L. DasovichM. GrantF.J. LockwoodL. LevinS.D. LeCielC. WaggieK. DayH. TopouzisS. KramerJ. KuestnerR. ChenZ. FosterD. Parrish-NovakJ. GrossJ.A. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.Nat. Immunol.20045775276010.1038/ni1084 15184896
     [Google Scholar]
  38. FeldM. GarciaR. BuddenkotteJ. KatayamaS. LewisK. MuirheadG. HeveziP. PlesserK. SchrumpfH. KrjutskovK. SergeevaO. MüllerH.W. TsokaS. KereJ. DillonS.R. SteinhoffM. HomeyB. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves.J. Allergy Clin. Immunol.20161382500508.e2410.1016/j.jaci.2016.02.020 27212086
     [Google Scholar]
  39. KeamS.J. Nemolizumab: First approval.Drugs202282101143115010.1007/s40265‑022‑01741‑z 35834124
     [Google Scholar]
  40. KabashimaK. FurueM. HanifinJ.M. PulkaG. WollenbergA. GalusR. EtohT. MiharaR. NakanoM. RuzickaT. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.J. Allergy Clin. Immunol.2018142411211130.e710.1016/j.jaci.2018.03.018 29753033
     [Google Scholar]
  41. KabashimaK. Study GroupNemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: Results from two phase III, long-term studies.Br. J. Dermatol.2022186464265110.1111/bjd.20873 34726262
     [Google Scholar]
  42. KabashimaK. MatsumuraT. KomazakiH. KawashimaM. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus.N. Engl. J. Med.2020383214115010.1056/NEJMoa1917006 32640132
     [Google Scholar]
  43. IgarashiA. KatsunumaT. MatsumuraT. KomazakiH. TakahashiH. MiuraK. HorinoS. YoshiharaS. MaedaS. AkashiM. HamahataY. NezuY. MasudaK. ShirakawaS. KatsunumaT. OhyaY. YanagidaN. TadakiH. FukuzawaM. KanekoH. TakahashiK. FunatoM. FutamuraM. KoderaM. TakasatoY. FujisawaT. KumeA. TaketaniT. MurakamiY. WakatsukiM. IgawaS. TomiitaM. SuzukiS. NaritaM. YoshidaK. KondoY. KiyomasuT. TakemuraY. MankiA. HideM. TanakaA. TezukaJ. IkedaM. YamaideF. NakanoT. Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.Br. J. Dermatol.20231901202810.1093/bjd/ljad268 37522351
     [Google Scholar]
  44. NakajimaS. IgyártóB.Z. HondaT. EgawaG. OtsukaA. Hara-ChikumaM. WatanabeN. ZieglerS.F. TomuraM. InabaK. MiyachiY. KaplanD.H. KabashimaK. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling.J. Allergy Clin. Immunol.2012129410481055.e610.1016/j.jaci.2012.01.063 22385635
     [Google Scholar]
  45. SoumelisV. RecheP.A. KanzlerH. YuanW. EdwardG. HomeyB. GillietM. HoS. AntonenkoS. LauermaA. SmithK. GormanD. ZurawskiS. AbramsJ. MenonS. McClanahanT. Waal-MalefytR. BazanF. KasteleinR.A. LiuY.J. Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP.Nat. Immunol.20023767368010.1038/ni805 12055625
     [Google Scholar]
  46. LiuY.J. Thymic stromal lymphopoietin: Master switch for allergic inflammation.J. Exp. Med.2006203226927310.1084/jem.20051745 16432252
     [Google Scholar]
  47. SimpsonE.L. ParnesJ.R. SheD. CrouchS. ReesW. MoM. van der MerweR. Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.J. Am. Acad. Dermatol.20198041013102110.1016/j.jaad.2018.11.059 30550828
     [Google Scholar]
  48. Guttman-YasskyE. PavelA.B. ZhouL. EstradaY.D. ZhangN. XuH. PengX. WenH.C. GovasP. GudiG. CaV. FangH. SalhiY. BackJ. ReddyV. BissonnetteR. MaariC. GrossmanF. WolffG. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.J. Allergy Clin. Immunol.20191442482493.e710.1016/j.jaci.2018.11.053 30738171
     [Google Scholar]
  49. NakagawaH. IizukaH. NemotoO. ShimabeM. FurukawaY. KikutaN. OotakiK. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.J. Dermatol. Sci.2020992828910.1016/j.jdermsci.2020.06.005 32651105
     [Google Scholar]
  50. WeidingerS. BieberT. CorkM.J. ReichA. WilsonR. QuaratinoS. StebeggM. BrennanN. GilbertS. O’MalleyJ.T. Porter-BrownB. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: Results of a phase IIa randomized placebo-controlled trial.Br. J. Dermatol.2023189553153910.1093/bjd/ljad240 37463508
     [Google Scholar]
  51. ChenY.L. Gutowska-OwsiakD. HardmanC.S. WestmorelandM. MacKenzieT. CifuentesL. WaitheD. Lloyd-LaveryA. MarquetteA. LondeiM. OggG. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis.Sci. Transl. Med.201911515eaax294510.1126/scitranslmed.aax2945 31645451
     [Google Scholar]
  52. NogralesK.E. ZabaL.C. ShemerA. Fuentes-DuculanJ. CardinaleI. KikuchiT. RamonM. BergmanR. KruegerJ.G. Guttman-YasskyE. IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells.J. Allergy Clin. Immunol.2009123612441252.e210.1016/j.jaci.2009.03.041 19439349
     [Google Scholar]
  53. DansoM.O. van DrongelenV. MulderA. van EschJ. ScottH. van SmedenJ. El GhalbzouriA. BouwstraJ.A. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents.J. Invest. Dermatol.201413471941195010.1038/jid.2014.83 24518171
     [Google Scholar]
  54. SaS.M. ValdezP.A. WuJ. JungK. ZhongF. HallL. KasmanI. WinerJ. ModrusanZ. DanilenkoD.M. OuyangW. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.J. Immunol.200717842229224010.4049/jimmunol.178.4.2229 17277128
     [Google Scholar]
  55. Guttman-YasskyE. BrunnerP.M. NeumannA.U. KhattriS. PavelA.B. MalikK. SingerG.K. BaumD. GilleaudeauP. Sullivan-WhalenM. RoseS. Jim OnS. LiX. Fuentes-DuculanJ. EstradaY. GarcetS. Traidl-HoffmannC. KruegerJ.G. LebwohlM.G. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.J. Am. Acad. Dermatol.2018785872881.e610.1016/j.jaad.2018.01.016 29353025
     [Google Scholar]
  56. BrunnerP.M. PavelA.B. KhattriS. LeonardA. MalikK. RoseS. Jim OnS. VekariaA.S. Traidl-HoffmannC. SingerG.K. BaumD. GilleaudeauP. Sullivan-WhalenM. Fuentes-DuculanJ. LiX. ZhengX. EstradaY. GarcetS. WenH.C. GonzalezJ. CoatsI. CuetoI. NeumannA.U. LebwohlM.G. KruegerJ.G. Guttman-YasskyE. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.J. Allergy Clin. Immunol.2019143114215410.1016/j.jaci.2018.07.028 30121291
     [Google Scholar]
  57. HamiltonJ.D. Suárez-FariñasM. DhingraN. CardinaleI. LiX. KosticA. MingJ.E. RadinA.R. KruegerJ.G. GrahamN. YancopoulosG.D. PirozziG. Guttman-YasskyE. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.J. Allergy Clin. Immunol.201413461293130010.1016/j.jaci.2014.10.013 25482871
     [Google Scholar]
  58. KhattriS. ShemerA. RozenblitM. DhingraN. CzarnowickiT. FinneyR. GilleaudeauP. Sullivan-WhalenM. ZhengX. XuH. CardinaleI. de Guzman StrongC. GonzalezJ. Suárez-FariñasM. KruegerJ.G. Guttman-YasskyE. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.J. Allergy Clin. Immunol.201413361626163410.1016/j.jaci.2014.03.003 24786238
     [Google Scholar]
  59. TintleS. ShemerA. Suárez-FariñasM. FujitaH. GilleaudeauP. Sullivan-WhalenM. Johnson-HuangL. ChiricozziA. CardinaleI. DuanS. BowcockA. KruegerJ.G. Guttman-YasskyE. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response.J. Allergy Clin. Immunol.20111283583593e4, 4.10.1016/j.jaci.2011.05.042 21762976
     [Google Scholar]
  60. BrunnerP.M. KhattriS. GarcetS. FinneyR. OlivaM. DuttR. Fuentes-DuculanJ. ZhengX. LiX. BonifacioK.M. KunjraviaN. CoatsI. CuetoI. GilleaudeauP. Sullivan-WhalenM. Suárez-FariñasM. KruegerJ.G. Guttman-YasskyE. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.J. Allergy Clin. Immunol.2016138116917810.1016/j.jaci.2015.12.1323 26948076
     [Google Scholar]
  61. Guttman-YasskyE. UngarB. MalikK. DicksteinD. SuprunM. EstradaY.D. XuH. PengX. OlivaM. ToddD. LabudaT. Suarez-FarinasM. BissonnetteR. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis.J. Allergy Clin. Immunol.2017140410321042.e1310.1016/j.jaci.2017.01.027 28238742
     [Google Scholar]
  62. KoppT. RiedlE. BangertC. BowmanE.P. GreiseneggerE. HorowitzA. KittlerH. BlumenscheinW.M. McClanahanT.K. MarburyT. ZachariaeC. XuD. HouX.S. MehtaA. ZandvlietA.S. MontgomeryD. van AarleF. KhaliliehS. Clinical improvement in psoriasis with specific targeting of interleukin-23.Nature2015521755122222610.1038/nature14175 25754330
     [Google Scholar]
  63. KhattriS. BrunnerP.M. GarcetS. FinneyR. CohenS.R. OlivaM. DuttR. Fuentes-DuculanJ. ZhengX. LiX. BonifacioK.M. KunjraviaN. CoatsI. CuetoI. GilleaudeauP. Sullivan-WhalenM. Suárez-FariñasM. KruegerJ.G. Guttman-YasskyE. Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis.Exp. Dermatol.2017261283510.1111/exd.13112 27304428
     [Google Scholar]
  64. SaekiH. KabashimaK. TokuraY. MurataY. ShiraishiA. TamamuraR. RandazzoB. ImanakaK. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: A randomized, double-blind, placebo-controlled, phase II study.Br. J. Dermatol.2017177241942710.1111/bjd.15493 28338223
     [Google Scholar]
  65. GuC. WuL. LiX. IL-17 family: Cytokines, receptors and signaling.Cytokine201364247748510.1016/j.cyto.2013.07.022 24011563
     [Google Scholar]
  66. UngarB. PavelA.B. LiR. KimmelG. NiaJ. HashimP. KimH.J. ChimaM. VekariaA.S. EstradaY. XuH. PengX. SingerG.K. BaumD. MansouriY. TaliercioM. Guttman-YasskyE. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.J. Allergy Clin. Immunol.2021147139439710.1016/j.jaci.2020.04.055 32428528
     [Google Scholar]
  67. Ramirez-CarrozziV. SambandamA. LuisE. LinZ. JeetS. LeschJ. HackneyJ. KimJ. ZhouM. LaiJ. ModrusanZ. SaiT. LeeW. XuM. CaplaziP. DiehlL. de VossJ. BalazsM. GonzalezL.Jr SinghH. OuyangW. PappuR. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner.Nat. Immunol.201112121159116610.1038/ni.2156 21993848
     [Google Scholar]
  68. VandeghinsteN. KlattigJ. JagerschmidtC. LavazaisS. MarsaisF. HaasJ.D. AubervalM. LaufferF. MoranT. OngenaertM. Van BalenM. DupontS. LepescheuxL. GarciaT. HärtleS. EyerichK. FallonP.G. BrysR. SteidlS. Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis.J. Invest. Dermatol.201813871555156310.1016/j.jid.2018.01.036 29474945
     [Google Scholar]
  69. ThaçiD. SinghD. LeeM. TimmisH. JacobsD. PassierP. RohrerS. BeetensJ. PhungD. SondagE. BabicG. WürthG. KloepferP. HärtleS. HüttnerS. Phase 1 and 2 randomized clinical studies determine lack of efficacy for Anti-IL-17C antibody MOR106 in moderate-severe atopic dermatitis.J. Clin. Med.20221123724410.3390/jcm11237244 36498818
     [Google Scholar]
  70. BissonnetteR. AbramovitsW. Saint-Cyr ProulxÉ. LeeP. Guttman-YasskyE. ZovkoE. SigmundR. WillcoxJ. BieberT. Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIA study.J. Eur. Acad. Dermatol. Venereol.202337354955710.1111/jdv.18727 36376738
     [Google Scholar]
  71. GhoreschiK. GadinaM. Jakpot! New small molecules in autoimmune and inflammatory diseases.Exp. Dermatol.201423171110.1111/exd.12265 24131352
     [Google Scholar]
  72. FlanaganM.E. BlumenkopfT.A. BrissetteW.H. BrownM.F. CasavantJ.M. Shang-PoaC. DotyJ.L. ElliottE.A. FisherM.B. HinesM. KentC. KudlaczE.M. LillieB.M. MagnusonK.S. McCurdyS.P. MunchhofM.J. PerryB.D. SawyerP.S. StrelevitzT.J. SubramanyamC. SunJ. WhippleD.A. ChangelianP.S. Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.J. Med. Chem.201053248468848410.1021/jm1004286 21105711
     [Google Scholar]
  73. PappK.A. MenterM.A. RamanM. DischD. SchlichtingD.E. GaichC. MaciasW. ZhangX. JanesJ.M. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis.Br. J. Dermatol.201617461266127610.1111/bjd.14403 26800231
     [Google Scholar]
  74. BaoL. ZhangH. ChanL.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis.JAK-STAT201323e2413710.4161/jkst.24137 24069552
     [Google Scholar]
  75. WaldmannT.A. The biology of IL-15: Implications for cancer therapy and the treatment of autoimmune disorders.J. Investig. Dermatol. Symp. Proc.2013161S28S3010.1038/jidsymp.2013.8 24326545
     [Google Scholar]
  76. XingL. DaiZ. JabbariA. CeriseJ.E. HigginsC.A. GongW. de JongA. HarelS. DeStefanoG.M. RothmanL. SinghP. PetukhovaL. Mackay-WigganJ. ChristianoA.M. ClynesR. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.Nat. Med.20142091043104910.1038/nm.3645 25129481
     [Google Scholar]
  77. Guttman-YasskyE. SilverbergJ.I. NemotoO. FormanS.B. WilkeA. PrescillaR. de la PeñaA. NunesF.P. JanesJ. GamaloM. DonleyD. PaikJ. DeLozierA.M. NickoloffB.J. SimpsonE.L. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.J. Am. Acad. Dermatol.2019804913921.e910.1016/j.jaad.2018.01.018 29410014
     [Google Scholar]
  78. Guttman-YasskyE. Primary Results from a Phase 2b, Randomized, Placebo-Controlled Trial of Upadacitinib for Patients with Atopic Dermatitis.2018 Annual MeetingSan Diego, USA2018
     [Google Scholar]
  79. ReichK. TeixeiraH.D. de Bruin-WellerM. BieberT. SoongW. KabashimaK. WerfelT. ZengJ. HuangX. HuX. HendricksonB.A. LadizinskiB. ChuA.D. SilverbergJ.I. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): Results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2021397102902169218110.1016/S0140‑6736(21)00589‑4 34023009
     [Google Scholar]
  80. BlauveltA. TeixeiraH.D. SimpsonE.L. CostanzoA. De Bruin-WellerM. BarbarotS. PrajapatiV.H. LioP. HuX. WuT. LiuJ. LadizinskiB. ChuA.D. EyerichK. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis.JAMA Dermatol.202115791047105510.1001/jamadermatol.2021.3023 34347860
     [Google Scholar]
  81. GooderhamM.J. FormanS.B. BissonnetteR. BeebeJ.S. ZhangW. BanfieldC. ZhuL. PapacharalambousJ. VincentM.S. PeevaE. Efficacy and safety of oral Janus Kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: A phase 2 randomized clinical trial.JAMA Dermatol.2019155121371137910.1001/jamadermatol.2019.2855 31577341
     [Google Scholar]
  82. ReichK. ThyssenJ.P. BlauveltA. EyerichK. SoongW. RiceZ.P. HongH.C. KatohN. ValenzuelaF. DiBonaventuraM. BrattT.A. ZhangF. ClibbornC. RojoR. ValdezH. KerkmannU. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial.Lancet20224001034827328210.1016/S0140‑6736(22)01199‑0 35871814
     [Google Scholar]
  83. BissonnetteR. MaariC. FormanS. BhatiaN. LeeM. FowlerJ. TyringS. PariserD. SofenH. DhawanS. ZookM. ZammitD.J. UsanskyH. DenisL. RaoN. SongT. PavelA.B. Guttman-YasskyE. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: Results from a randomized double‐blind placebo‐controlled study.Br. J. Dermatol.2019181473374210.1111/bjd.17932 30919407
     [Google Scholar]
  84. PuarN. ChovatiyaR. PallerA.S. New treatments in atopic dermatitis.Ann. Allergy Asthma Immunol.20211261213110.1016/j.anai.2020.08.016 32818591
     [Google Scholar]
  85. Guide To PharmacologySynthetic organic.2024Available From: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8985
    [Google Scholar]
  86. WerfelT. LaytonG. YeadonM. WhitlockL. OsterlohI. JimenezP. LiuW. LynchV. AsherA. TsianakasA. PurkinsL. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis.J. Allergy Clin. Immunol.2019143518301837.e410.1016/j.jaci.2018.07.047 30414855
     [Google Scholar]
  87. KlonowskaJ. GleńJ. NowickiR. TrzeciakM. New cytokines in the pathogenesis of atopic Dermatitis-New therapeutic targets.Int. J. Mol. Sci.20181910308610.3390/ijms19103086 30304837
     [Google Scholar]
  88. KupperT.S. BallardD.W. ChuaA.O. McGuireJ.S. FloodP.M. HorowitzM.C. LangdonR. LightfootL. GublerU. Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1.J. Exp. Med.198616462095210010.1084/jem.164.6.2095 2431094
     [Google Scholar]
  89. PareekA. KumariL. PareekA. ChaudharyS. RatanY. JanmedaP. ChuturgoonS. ChuturgoonA. Unraveling atopic dermatitis: Insights into pathophysiology, therapeutic advances, and future perspectives.Cells202413542510.3390/cells13050425 38474389
     [Google Scholar]
  90. MatarazzoL. Hernandez SantanaY.E. WalshP.T. FallonP.G. The IL-1 cytokine family as custodians of barrier immunity.Cytokine202215415589010.1016/j.cyto.2022.155890 35462264
     [Google Scholar]
  91. IhimS.A. AbubakarS.D. ZianZ. SasakiT. SaffariounM. MalekniaS. AziziG. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.Front. Immunol.20221391997310.3389/fimmu.2022.919973 36032110
     [Google Scholar]
  92. HouT. SunX. ZhuJ. HonK.L. JiangP. ChuI.M.T. TsangM.S.M. LamC.W.K. ZengH. WongC.K. IL-37 Ameliorating allergic inflammation in atopic dermatitis through regulating microbiota and AMPK-MTOR signaling Pathway-Modulated Autophagy Mechanism.Front. Immunol.20201175210.3389/fimmu.2020.00752 32411145
     [Google Scholar]
  93. KonishiH. TsutsuiH. MurakamiT. Yumikura-FutatsugiS. YamanakaK. TanakaM. IwakuraY. SuzukiN. TakedaK. AkiraS. NakanishiK. MizutaniH. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions.Proc. Natl. Acad. Sci. USA20029917113401134510.1073/pnas.152337799 12151598
     [Google Scholar]
  94. WangX. WangL. WenX. ZhangL. JiangX. HeG. Interleukin-18 and IL-18BP in inflammatory dermatological diseases.Front. Immunol.20231495536910.3389/fimmu.2023.955369 36742296
     [Google Scholar]
  95. van den BogaardE.H. BergboerJ.G.M. Vonk-BergersM. van Vlijmen-WillemsI.M.J.J. HatoS.V. van der ValkP.G.M. SchröderJ.M. JoostenI. ZeeuwenP.L.J.M. SchalkwijkJ. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis.J. Clin. Invest.2013123291792710.1172/JCI65642 23348739
     [Google Scholar]
  96. TrikhaP. LeeD.A. The role of AhR in transcriptional regulation of immune cell development and function.Biochim. Biophys. Acta Rev. Cancer20201873118833510.1016/j.bbcan.2019.188335 31816350
     [Google Scholar]
  97. PallerA.S. Stein GoldL. SoungJ. TallmanA.M. RubensteinD.S. GooderhamM. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.J. Am. Acad. Dermatol.202184363263810.1016/j.jaad.2020.05.135 32502588
     [Google Scholar]
  98. ShaoM. HussainZ. ThuH.E. KhanS. KatasH. AhmedT.A. TripathyM. LengJ. QinH.L. BukhariS.N.A. Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease.Colloids Surf. B Biointerfaces2016147147549110.1016/j.colsurfb.2016.08.027 27592075
     [Google Scholar]
  99. SoutoE.B. Dias-FerreiraJ. OliveiraJ. Sanchez-LopezE. Lopez-MachadoA. EspinaM. GarciaM.L. SoutoS.B. Martins-GomesC. SilvaA.M. Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems.Int. J. Mol. Sci.20192022565910.3390/ijms20225659 31726723
     [Google Scholar]
  100. SaleemS. IqubalM.K. GargS. AliJ. BabootaS. Trends in nanotechnology-based delivery systems for dermal targeting of drugs: An enticing approach to offset psoriasis.Expert Opin. Drug Deliv.202017681783810.1080/17425247.2020.1758665 32315216
     [Google Scholar]
  101. RaoN.V. KoH. LeeJ. ParkJ.H. Recent progress and advances in stimuli responsive polymers for cancer therapy.Front. Bioeng. Biotechnol.20186111010.3389/fbioe.2018.00110 30159310
     [Google Scholar]
  102. DamianiG. EggenhöffnerR. PigattoP.D.M. BragazziN.L. Nanotechnology meets atopic dermatitis: Current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature.Bioact. Mater.2019438038610.1016/j.bioactmat.2019.11.003 31872162
     [Google Scholar]
  103. HeinzK.C. BeaudartC. WillemsD. WiethoffI. HiligsmannM. Cost-Effectiveness of emerging Treatments for atopic dermatitis: A systematic review. Pharmaco.Eco.202341111415143510.1007/s40273‑023‑01293‑4 37392363
     [Google Scholar]
  104. HeinzK.C. WillemsD. HiligsmannM. Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective.J. Med. Econ.202225149150210.1080/13696998.2022.2059220 35350959
     [Google Scholar]
/content/journals/cpb/10.2174/0113892010311098240530104530
Loading
Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy
Current Pharmaceutical Biotechnology 26, 1617 (2025); https://doi.org/10.2174/0113892010311098240530104530
/content/journals/cpb/10.2174/0113892010311098240530104530
/content/journals/cpb/10.2174/0113892010311098240530104530
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Atopic dermatitis; biologicals; biomarkers; interleukins; janus kinases; monoclonal antibodies

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test